{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-005582","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.550626+00:00","generated_at":"2026-06-20T07:19:14.741560+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Jasper Therapeutics closes $103.5M public offering of 69M shares at $1.50/share","bullets":["Closed underwritten offering of 69,000,000 shares at $1.50, including 9M option shares.","Gross proceeds of approximately $103.5M before underwriting discounts and expenses.","Offering made under effective shelf registration statement (File No. 333-267777) filed Oct 2022.","Lead book-running managers: Credit Suisse Securities and William Blair; Oppenheimer as passive book-runner.","Company focuses on c-Kit antibody therapies for chronic spontaneous urticaria, MDS, and transplant conditioning."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-005582","json":"https://secwatch.observer/filing/0001213900-23-005582.json","markdown":"https://secwatch.observer/filing/0001213900-23-005582.md","text":"https://secwatch.observer/filing/0001213900-23-005582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023005582/0001213900-23-005582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023005582/ea172298-8k_jasper.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T07:19:14.741560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}